At least 46 drugs developed and marketed by biotech companies are expected to have more than $500 million in 2013 sales. Of those, 26 are expected to bring in more $1 billion in annual sales. Seven drugs are expected to cross the $500 million mark in 2013: Abraxane nab-paclitaxel; Complera emtricitabine/tenofovir/rilpivirine; Elaprase idursulfase; Letairis ambrisentan; Lialda mesalamine; Tecfidera dimethyl fumarate; and Xifaxan rifaximin.

Product sales as reported by companies listed below, unless otherwise noted. Included are drugs developed by biotechs that were acquired - Cephalon Inc.; Genentech Inc.; Genzyme Corp.; MedImmune LLC; Onyx Pharmaceuticals Inc.; and OSI Pharmaceuticals LLC - but still maintain a separate commercial presence from their acquirer. (A) 2013 sales projected from 2013 nine-month sales from UCB Group (Euronext:UCB) and sales for the six months ended Sept. 30, 2013 from Astellas Pharma Inc. (Tokyo:4503); (B) Sales of